

Steven H Spergel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4880515/publications.pdf>

Version: 2024-02-01

36
papers

1,737
citations

304743

22
h-index

330143

37
g-index

39
all docs

39
docs citations

39
times ranked

1859
citing authors

#	ARTICLE	IF	CITATIONS
1	Practical olefin hydroamination with nitroarenes. <i>Science</i> , 2015, 348, 886-891.	12.6	387
2	Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8973-8995.	6.4	212
3	Selective Itk Inhibitors Block T-Cell Activation and Murine Lung Inflammation. <i>Biochemistry</i> , 2004, 43, 11056-11062.	2.5	102
4	Cupric bromide mediated oxidation of 4-carboxyoxazolines to the corresponding oxazoles. <i>Journal of Organic Chemistry</i> , 1993, 58, 4494-4496.	3.2	71
5	Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 3706-3712.	2.2	65
6	Synthesis and antiviral activity of novel isonucleoside analogs. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 1221-1229.	6.4	62
7	Molecular design, synthesis, and structure-Activity relationships leading to the potent and selective p56lck inhibitor BMS-243117. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2145-2149.	2.2	59
8	Rational Design and Synthesis of an Orally Active Indolopyridone as a Novel Conformationally Constrained Cannabinoid Ligand Possessing Antiinflammatory Properties. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 2110-2116.	6.4	59
9	Identification of <i>N</i> -Methyl Nicotinamide and <i>N</i> -Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8953-8972.	6.4	59
10	Biphenylsulfonamide Endothelin Receptor Antagonists. 4. Discovery of N-[[[(4,5-Dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), A Highly Potent and Orally Active ETA Selective Antagonist. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 125-137.	6.4	58
11	Imidazoquinoxaline Src-Family Kinase p56Lck Inhibitors: A SAR, QSAR, and the Discovery of (S)-N-(2-Chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo-[1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a Potent and Orally Active Inhibitor with Excellent in Vivo Antiinflammatory Activity. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 4517-4529.	6.4	57
12	A practical method for the preparation of α -chloroketones of N-carbamate protected α -aminoacids. <i>Tetrahedron Letters</i> , 1997, 38, 3175-3178.	1.4	51
13	Synthesis of benzazepinone and 3-methylbenzothiazepinone analogs of diltiazem. <i>Journal of Organic Chemistry</i> , 1990, 55, 5572-5579.	3.2	50
14	Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56Lck. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 1361-1364.	2.2	39
15	Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2411-2415.	2.2	36
16	One-Pot Synthesis of Azaindoles via Palladium-Catalyzed α -Heteroarylation of Ketone Enolates. <i>Journal of Organic Chemistry</i> , 2010, 75, 5316-5319.	3.2	36
17	Aminodiol HIV Protease Inhibitors. Synthesis And Structure-Activity Relationships Of P1/P1' Compounds: A Correlation between Lipophilicity and Cytotoxicity. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 1991-2007.	6.4	33
18	Biphenylsulfonamide Endothelin Receptor Antagonists. 2. Discovery of α -Oxazolyl Biphenylsulfonamides as a New Class of Potent, Highly Selective ETA Antagonists. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3111-3117.	6.4	32

#	ARTICLE	IF	CITATIONS
19	Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56Lck inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 6061-6066.	2.2	31
20	Novel Tricyclic Inhibitors of I κ B Kinase. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1994-2005.	6.4	25
21	Discovery of highly potent, selective, covalent inhibitors of JAK3. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4622-4625.	2.2	24
22	Synthesis and SAR of novel imidazoquinoxaline-Based Lck inhibitors: improvement of cell potency. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 3153-3156.	2.2	23
23	Stereoelectronic effects in nucleophilic addition to a bicyclic ketone: an interpretation. <i>Tetrahedron Letters</i> , 1992, 33, 293-296.	1.4	21
24	1-benzazepin-2-one calcium channel blockers ^{VI} . Receptor-binding model and possible relationship to desmethoxyverapamil. <i>Bioorganic and Medicinal Chemistry</i> , 1993, 1, 285-307.	3.0	19
25	Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of I κ B kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2646-2649.	2.2	19
26	Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 908-912.	2.8	17
27	Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4908-4913.	2.2	12
28	Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: Synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 383-386.	2.2	11
29	Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 306-311.	2.8	11
30	I \pm -hydroxyamide derived aminodiols as potent inhibitors of hiv protease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1995, 5, 1729-1734.	2.2	10
31	Biphenylsulfonamide Endothelin Receptor Antagonists. Part 3: Structure ^{Activity} Relationship of 4 ϵ -Heterocyclic Biphenylsulfonamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 517-520.	2.2	10
32	Conformationally constrained calcium channel blockers: Novel mimics of 1-benzazepin-2-ones. <i>Bioorganic and Medicinal Chemistry</i> , 1993, 1, 309-325.	3.0	9
33	Novel tricyclic inhibitors of IKK2: Discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 7006-7012.	2.2	9
34	Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2470-2474.	2.2	6
35	The synthesis of a conformationally rigid calcium channel blocker. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1992, 2, 95-98.	2.2	5
36	Synthesis and absolute configuration of (+)-2,3,3-trimethyl-2-hydroxybutanoic acid. <i>Tetrahedron: Asymmetry</i> , 1995, 6, 2893-2894.	1.8	5